NRX Pharmaceuticals (NRXP) said Tuesday its subsidiary Hope Therapeutics has entered into a definitive agreement to acquire the Kadima Neuropsychiatry Institute, an interventional psychiatry clinic based in California.
Financial terms of the transaction were not disclosed.
Kadima founder and medical director Dr. David Feifel will join Hope as its first chief medical innovation officer upon the closing of the acquisition, the company said.
Feifel has served as an elected member of the American College of Neuropharmacology and has held roles in multiple clinical trials for CNS therapies, according to the statement.
Shares of NRX Pharmaceuticals were up 2.6% in recent trading.
Price: 2.14, Change: +0.05, Percent Change: +2.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.